We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthpeak's Q4 FFO Beats Estimates, Same-Store NOI Rises
Read MoreHide Full Article
Healthpeak Properties, Inc. (DOC - Free Report) reported fourth-quarter 2024 funds from operations (FFO) as adjusted per share of 46 cents, beating the Zacks Consensus Estimate by a penny. The reported figure remained unchanged from the prior-year quarter.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Results reflect better-than-anticipated revenues. Growth in total merger-combined same-store cash (adjusted) net operating income (NOI) was witnessed across the portfolio. However, higher interest expenses affected the results to some extent. The company issued its 2025 guidance.
This healthcare real estate investment trust (REIT) generated revenues of $698 million, outpacing the Zacks Consensus Estimate of $694 million. The figure climbed 26.1% year over year.
In 2024, FFO, as adjusted, was $1.81 per share, in line with the Zacks Consensus Estimate. The reported figure improved 1.7% year over year. Full-year revenues of $2.70 billion increased 23.8% from the previous year.
Healthpeak Properties, Inc. Price, Consensus and EPS Surprise
In the fourth quarter, Healthpeak reported 5.4% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI.
It witnessed 3.1% and 4.9% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI for its outpatient medical and lab segments, respectively. The CCRC segment reported growth of 22.3%.
During the reported quarter, Healthpeak executed lab new and renewal leases totaling 652,000 square feet. For the outpatient medical portfolio, new and renewal leases aggregated 879,000 square feet.
However, interest expenses jumped 33.6% year over year to $70.5 million.
DOC’s Balance Sheet
Healthpeak exited the fourth quarter with cash and cash equivalents of $119.8 million, down from $180.4 million as of Sept. 30, 2024. Its net debt to adjusted EBITDAre was 5.2X as of Dec. 31, 2024.
DOC’s Dividend Update
On Feb. 3, Healthpeak’s board of directors declared a quarterly cash dividend of 30.5 cents per common share. This reflects a 1.7% increase from the prior quarter. The dividend will be paid out on Feb. 26, to shareholders on record as of Feb. 14, 2025.
DOC’s 2025 Outlook
The company expects FFO as adjusted per share to be between $1.81 and $1.87. The Zacks Consensus Estimate is presently pegged at $1.86, which is within expectations.
The total merger-combined same-store cash (adjusted) NOI growth is estimated to be in the range of 3.0-4.0%.
Healthpeak currently carries a Zacks Rank #3 (Hold).
Upcoming Earnings Releases
We now look forward to the earnings releases of other healthcare REITs, such as Welltower, Inc. (WELL - Free Report) and Ventas, Inc. (VTR - Free Report) , slated to report on Feb. 11 and Feb. 12, respectively.
The Zacks Consensus Estimate for Ventas’ fourth-quarter 2024 FFO per share stands at 80 cents, indicating a 5.3% rise year over year. VTR currently has a Zacks Rank #3.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Healthpeak's Q4 FFO Beats Estimates, Same-Store NOI Rises
Healthpeak Properties, Inc. (DOC - Free Report) reported fourth-quarter 2024 funds from operations (FFO) as adjusted per share of 46 cents, beating the Zacks Consensus Estimate by a penny. The reported figure remained unchanged from the prior-year quarter.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Results reflect better-than-anticipated revenues. Growth in total merger-combined same-store cash (adjusted) net operating income (NOI) was witnessed across the portfolio. However, higher interest expenses affected the results to some extent. The company issued its 2025 guidance.
This healthcare real estate investment trust (REIT) generated revenues of $698 million, outpacing the Zacks Consensus Estimate of $694 million. The figure climbed 26.1% year over year.
In 2024, FFO, as adjusted, was $1.81 per share, in line with the Zacks Consensus Estimate. The reported figure improved 1.7% year over year. Full-year revenues of $2.70 billion increased 23.8% from the previous year.
Healthpeak Properties, Inc. Price, Consensus and EPS Surprise
Healthpeak Properties, Inc. price-consensus-eps-surprise-chart | Healthpeak Properties, Inc. Quote
Behind DOC’s Earnings Headlines
In the fourth quarter, Healthpeak reported 5.4% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI.
It witnessed 3.1% and 4.9% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI for its outpatient medical and lab segments, respectively. The CCRC segment reported growth of 22.3%.
During the reported quarter, Healthpeak executed lab new and renewal leases totaling 652,000 square feet. For the outpatient medical portfolio, new and renewal leases aggregated 879,000 square feet.
However, interest expenses jumped 33.6% year over year to $70.5 million.
DOC’s Balance Sheet
Healthpeak exited the fourth quarter with cash and cash equivalents of $119.8 million, down from $180.4 million as of Sept. 30, 2024. Its net debt to adjusted EBITDAre was 5.2X as of Dec. 31, 2024.
DOC’s Dividend Update
On Feb. 3, Healthpeak’s board of directors declared a quarterly cash dividend of 30.5 cents per common share. This reflects a 1.7% increase from the prior quarter. The dividend will be paid out on Feb. 26, to shareholders on record as of Feb. 14, 2025.
DOC’s 2025 Outlook
The company expects FFO as adjusted per share to be between $1.81 and $1.87. The Zacks Consensus Estimate is presently pegged at $1.86, which is within expectations.
The total merger-combined same-store cash (adjusted) NOI growth is estimated to be in the range of 3.0-4.0%.
Healthpeak currently carries a Zacks Rank #3 (Hold).
Upcoming Earnings Releases
We now look forward to the earnings releases of other healthcare REITs, such as Welltower, Inc. (WELL - Free Report) and Ventas, Inc. (VTR - Free Report) , slated to report on Feb. 11 and Feb. 12, respectively.
The Zacks Consensus Estimate for Welltower’s fourth-quarter 2024 FFO per share is pegged at $1.12, implying a 16.7% year-over-year increase. WELL currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Ventas’ fourth-quarter 2024 FFO per share stands at 80 cents, indicating a 5.3% rise year over year. VTR currently has a Zacks Rank #3.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.